~~<i id='B971745C83'><strike id='B971745C83'><tt id='B971745C83'><pre id='B971745C83'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：hotspot 2025-10-01 10:58:36 - browse：3

WASHINGTON — Back in 1980, when the Food and Drug Administration approved the use of lead acetate in hair dyes, little was known about the way skin absorbs toxic chemicals.

The skin — and the scalp in particular — were considered tough barriers to break, and many public health officials believed that even if small amounts of lead got through, or were inhaled, it couldn’t really hurt anyone.

But in science, 37 years is an eon. So a coalition of environmental groups, academics, and consumer advocates is pushing FDA to take lead acetate off the market. It is now permitted as a color additive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： At ASCO, AstraZeneca reports strong data for breast cancer drug

leisure time

hotspot

leisure time

hotspot

entertainment

focus

AlexHogan/STATHospitalsoncedoveheadfirstintoventurecapitalwithsplashyheadlinesandattention-grabbingn

WSS

FDA's Pazdur wants cancer trials to range beyond China alone

NIH documents show early flaws of $1.6 billion long Covid program

After Optum profits sink, UnitedHealth makes changes

HIV drugs protect against transmission, even in unprotected sex

Surge in Apellis stock fueled by confidence in safety of its eye drug

Indictment alleges Trump's ex

focus

knowledge

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Kaiser's Risant Health gobbled up Geisinger. Who is next?

After affirmative action ruling, medical educators look to 'holistic review'

Timeline: How the deadly wildfires took over Maui day by day

Medicare details structure of new drug price negotiation program

Novo Nordisk touts Wegovy study, but still struggling with supply

The high cost of giving birth even with insurance

Surge in Apellis stock fueled by confidence in safety of its eye drug

How to save PrEP access — and even expand it

Shifting the focus from loneliness to social health

hotspot

Intellia reports positive results for its CRISPR

With trial win, GSK could get blood cancer drug back on market

With trial win, GSK could get blood cancer drug back on market

The Pandemic Treaty must support building strong health systems

Cord blood banking comes at a high cost to babies

The Pandemic Treaty must support building strong health systems

leisure time

hotspot

entertainment

focus